AstraZeneca has announced a jump in sales in recent months after a surge in demand for cancer drugs, as the pharmaceutical giant prepares to plug 50 billion dollars (£37 billion) into its US expansion ...

This landmark investment reflects not only America's importance but also our confidence in our innovative medicines to transform global health and power AstraZeneca's ambition to deliver $80 billion ...

Cambridge headquartered AstraZeneca saw its UK share price rocket 328p to 11,118 and its market cap soar to £173.49 billion after a stunning set of results for the first half and second quarter of ...

Barclays today said half-year pre-tax profits rose 23% to £5.2 billion, boosted by a 28% improvement in the second quarter of ...

In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...

Total revenue rose 11 per cent to $28bn (£12.98bn) in the first half of the year, driven by double-digit growth in Oncology ...

Revenue from oncology products made up 43 per cent of Astrazeneca's revenue in the first half of 2025, up 15 per cent year on ...

The AstraZeneca share price has been treading water for the past few years, but first-half results add strength to rising ...

Product sales rose 11% to $13.80 billion, or 95.4% of the total revenue, thanks to double-digit growth in Oncology and ...

The pharmaceutical giant said second-quarter revenue increased to $14.46 billion from $12.94 billion. U.S. revenue was up 13% ...

Despite the EU and US agreeing a basic trade deal on Monday, the FTSE 100 and some European stocks fell on the day after a ...

The Anglo-Swedish pharmaceutical giant said Tuesday that for the second quarter, core earnings per share rose to $2.17 from $1.98 in the same period a year prior. Revenue increased to $14.46 billion ...